While business profit recovered to ¥25.8 billion in FY2026, impairment losses and other factors resulted in an operating loss of ¥70.7 billion and a loss attributable to owners of the parent of ¥88.0 billion. The key question will be how much of the FY2027 recovery plan, which targets business profit of ¥30.0 billion and net income of ¥45.0 billion, has been achieved by the end of the first half.
All recorded disclosures and news since the latest annual or semiannual filing. Switching watchpoints keeps the full history. Select an item to inspect its source.2026-11-13 〜 2026-11-17 · 2 of 2 items
Scroll the timeline →
Whether first-half business profit reaches at least ¥15.0 billion, equivalent to 50% of the full-year target of ¥30.0 billion
Whether revenue reaches at least ¥425.0 billion, equivalent to 50% of the full-year target of ¥850.0 billion
Whether any additional large impairment losses are recognized and, if so, whether the affected businesses and amounts are disclosed
Whether cash flow from operating activities exceeds the ¥38.9 billion recorded in the previous first half
Whether the full-year outlook is maintained at ¥30.0 billion for business profit, ¥70.0 billion for operating profit and ¥45.0 billion for net income
The company's ongoing themes and initiatives this watchpoint touches on.
FY2026 revenue was ¥873.2 billion and business profit was ¥25.8 billion, compared with an IFRS operating loss of ¥70.7 billion and a loss attributable to owners of the parent of ¥88.0 billion. Although the headline figures show a substantial loss, impairment losses of ¥50.354 billion were recognized in the Twaron business and ¥8.156 billion in the carbon fiber business, making it necessary to distinguish operating profit and loss from recurring business profit. Against the previous fiscal year's earnings level, FY2027-H1 will be a period for assessing how much ordinary earnings can be recovered with the post-impairment asset base.
For FY2027, the company expects business profit of ¥30.0 billion, ROE of 12% and business profit ROIC of 3%, positioning the year as part of the recovery toward business profit of ¥60.0 billion in FY2028. The financial summary forecasts operating profit of ¥70.0 billion and net income of ¥45.0 billion, reflecting a substantial difference in definition between business profit and IFRS operating profit. At the next results announcement, it will be important to see whether the company clearly discloses the reconciliation from business profit to operating profit, including the treatment of impairment losses, restructuring costs and gains or losses on business disposals.
Full-year revenue is planned at ¥850.0 billion, making ¥425.0 billion a simple first-half benchmark. However, the Materials business continues to face the effects of price competition and production-system restructuring, while pricing revisions and generic-drug penetration continue to affect Healthcare, making it difficult to assess progress toward the plan based on revenue alone. Volumes, price and mix, capacity utilization and the breakdown of fixed-cost reductions should be reviewed together by segment.
On the cash-flow side, the company generated ¥38.9 billion in cash flow from operating activities in the previous interim period, rising to ¥98.654 billion for FY2026 as a whole. In FY2027-H1, it will be important to confirm not only that operating cash flow remains positive, but also the level of free cash flow after capital expenditures, R&D expenses and restructuring payments. Even if the full-year outlook is maintained, the credibility of the earnings recovery plan would decline if first-half business profit falls materially below ¥15.0 billion or additional impairment losses are recognized.
Business profit (¥100 million)
Select a value or step to inspect its source.
Ordered by date. Disclosures and financial records differ from news and company threads; open each source to inspect it.
2026-11-05 · Awaiting publication
2026-11-14
· Awaiting publication
The prior-year comparison for this event
2025-11-05 disclosed · In ¥ millions; each quarter is cumulative from the start of the fiscal year. EPS is in yen.
Latest available: FY2027 Q2
Net salesBusiness scale
451,043JPY m
YoY unavailableOperating profitCore earnings
-54,082JPY m
YoY unavailableNewest first. The highlighted column is this event’s comparison. YoY uses the same period and accounting basis.
| Metric | FY2027 Q2 | FY2027 Q1 | FY2026 full year | FY2026 Q3 | FY2026 Q2Comparison | FY2026 Q1 | FY2025 full year | FY2025 Q3 |
|---|---|---|---|---|---|---|---|---|
| Net sales | 439,562↘ -2.5% YoY | 221,943↘ -8.7% YoY | 873,190↘ -13.2% YoY | 659,878↘ -12.7% YoY | 451,043YoY unavailable | 243,117YoY unavailable | 1,005,471YoY unavailable | 756,112YoY unavailable |
| Operating profit | 70,794YoY unavailable | 59,959↗ +2512.6% YoY | -70,714YoY unavailable | -53,773YoY unavailable | -54,082YoY unavailable | 2,295YoY unavailable | -71,828YoY unavailable | -43,727YoY unavailable |
| Ordinary profit | —YoY unavailable | —YoY unavailable | —YoY unavailable | —YoY unavailable | —YoY unavailable | —YoY unavailable | —YoY unavailable | —YoY unavailable |
| Net income | 52,541YoY unavailable | 45,106YoY unavailable | -88,003↘ -410.4% YoY | -58,970↘ -215.7% YoY | -54,835YoY unavailable | -740YoY unavailable | 28,347YoY unavailable | 50,980YoY unavailable |
| Earnings per share | 272.26YoY unavailable | 233.81YoY unavailable | -456.33↘ -410.1% YoY | -305.81↘ -215.5% YoY | -284.41YoY unavailable | -3.84YoY unavailable | 147.15YoY unavailable | 264.66YoY unavailable |